Trade Mark Journal No.2026/040 2 October 2026

WO0000001937523 (5,42)

Office of origin: United States of America

Date of International Registration:23 July 2026
Date of designation in the UK: 23 July 2026
Image for mark 1937523 RESILIENT PHARMACEUTICALS

"PHARMACEUTICALS"

International priority date claimed: 27 January 2026 (United States of America) (99618047)
Class 5
Pharmaceutical preparations, namely, prescription psychotropics; pharmaceutical preparations for managing and treating mental illnesses and psychiatric, psychological, and neurological disorders and conditions; psychopharmaceutical preparations for managing and treating diseases, disorders, and conditions related to the brain, HPA axis dysregulation, trauma, mood, thought, behavior, and perception; psychedelic therapeutic preparations for treating and managing PTSD, eating disorders, postpartum depression, alcohol use disorder, opioid and substance use disorder, generalized anxiety disorder, social anxiety disorder, major depressive disorder, and traumatic brain injury.
Class 42
Medical scientific research and development in the fields of psychotropics, psychedelic-assisted therapy, and psychopharmaceuticals; providing medical scientific research information in the fields of psychotropics, psychedelic-assisted therapy, and psychopharmaceuticals.

Resilient Pharmaceuticals, Inc.

Representative: Karen K. Won Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C, One Financial Center, Boston MA 02111, UNITED STATES OF AMERICA